LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Net Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Net Income
-$25.1m
CAGR 3-Years
18%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Net Income
$14.7m
CAGR 3-Years
-25%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Net Income
-€42.6m
CAGR 3-Years
16%
CAGR 5-Years
4%
CAGR 10-Years
-10%
Uniqure NV
NASDAQ:QURE
Net Income
-$235.1m
CAGR 3-Years
-23%
CAGR 5-Years
-7%
CAGR 10-Years
-12%
argenx SE
XBRU:ARGX
Net Income
-$22m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Net Income
-$381.1m
CAGR 3-Years
-82%
CAGR 5-Years
-36%
CAGR 10-Years
-31%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Net Income?
Net Income
-25.1m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Net Income amounts to -25.1m USD.

What is LAVA Therapeutics NV's Net Income growth rate?
Net Income CAGR 5Y
-21%

Over the last year, the Net Income growth was 40%. The average annual Net Income growth rates for LAVA Therapeutics NV have been 18% over the past three years , -21% over the past five years .

Back to Top